Gil M. Labrucherie
2016
In 2016, Gil M. Labrucherie earned a total compensation of $2.7M as Senior Vice President and Chief Financial Officer at Nektar Therapeutics, a 41% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $356,400 |
|---|---|
| Option Awards | $1,303,120 |
| Salary | $582,167 |
| Stock Awards | $489,596 |
| Other | $8,653 |
| Total | $2,739,936 |
Labrucherie received $1.3M in option awards, accounting for 48% of the total pay in 2016.
Labrucherie also received $356.4K in non-equity incentive plan, $582.2K in salary, $489.6K in stock awards and $8.7K in other compensation.
Rankings
In 2016, Gil M. Labrucherie's compensation ranked 3,553rd out of 14,075 executives tracked by ExecPay. In other words, Labrucherie earned more than 74.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,553 out of 14,075 | 75th |
Division Manufacturing | 1,235 out of 5,489 | 78th |
Major group Chemicals And Allied Products | 372 out of 1,895 | 80th |
Industry group Drugs | 270 out of 1,538 | 82nd |
Industry Pharmaceutical Preparations | 214 out of 1,176 | 82nd |
Source: SEC filing on April 30, 2018.
Labrucherie's colleagues
We found four more compensation records of executives who worked with Gil M. Labrucherie at Nektar Therapeutics in 2016.
2016
Howard Robin
Nektar Therapeutics
Chief Executive Officer
2016
John Nicholson
Nektar Therapeutics
Chief Operating Officer
2016
Stephen Doberstein
Nektar Therapeutics
Senior Vice President and Chief Research and Development Officer
2016
Maninder Hora
Nektar Therapeutics